SLT is a quick, simple, yet highly effective laser procedure that reduces the intraocular pressure associated with glaucoma.

It is used for the treatment of primary open-angle glaucoma and may be an alternative for those who have been treated unsuccessfully with other types of glaucoma surgery techniques, such as Argon Laser Trabeculoplasty (ALT) or pressure-lowering drops.

SLT is painless and there are no side effects to worry about.

How does glaucoma surgery work?

SLT uses short pulses of low-energy light to target the melanin or pigment in specific cells of the affected eye—leaving untreated portions of the trabecular meshwork unaffected. In response to this glaucoma surgery process, the body’s natural healing mechanisms rebuild these cells which leads to improved drainage and lowered intraocular pressure. SLT can lower the intraocular pressure by an average of 25% in over 75% of patients treated.

What happens during the glaucoma surgery procedure?

Prior to treatment, eye drops are administered to prepare the eye and provide mild anaesthesia. Gentle pulses of light are delivered through a specially designed microscope. The entire glaucoma process takes only a few minutes and when complete you may be treated with anti-inflammatory eye drops.

Can SLT be repeated?

SLT is a gentle, non-thermal and non-invasive procedure and the biggest advantage is that it can be performed multiple times if necessary. In the past repeat treatment of previous approaches in laser therapy were either limited or not possible.

Am I a good candidate for SLT?

Yes, if you:

  • have primary open-angle pseudoexfoliation, or pigmentary glaucoma
  • are intolerant of or have difficulty taking prescribed glaucoma medications
  • are currently undergoing glaucoma drug therapy and wish to combine it with SLT
  • have had failed ALT treatments previously.

For those that do not respond to SLT treatment, other forms of treatment—including traditional drug therapy—can still be very effective.

Selective laser trabeculoplasty was introduced worldwide in 1995, and it gained FDA approval for use in 2001.